Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sierra Oncology Inc (NQ: SRRA )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sierra Oncology Inc

< Previous 1 2 3 Next >
The Daily Biotech Pulse: Addex Terminates Parkinson's Study, Expanded Use Of Rhythm's Obesity Drug, FDA Approval For AbbVie's Skyrizi In Crohn's Disease
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
From Sierra Oncology
Via Business Wire
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
These biotech stocks face some key make-or-break events in June that could have big implication for their futures. 
Via InvestorPlace
3 Biotech Stocks to Buy Before They Boom
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
Recap: Sierra Oncology Q1 Earnings
Sierra Oncology (NASDAQ:SRRA) reported its Q1 earnings results on Friday, May 6, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Analyst Ratings for Sierra Oncology
Sierra Oncology (NASDAQ:SRRA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
From Sierra Oncology
Via Business Wire
Sierra Oncology Reports First Quarter 2022 Results
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
From Kuznicki Law PLLC
Via Business Wire
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
From Kahn Swick & Foti, LLC
Via Business Wire
The Week Ahead In Biotech (April 17-April 23): J&J, Abbott Earnings, Adcom Test For TG Therapeutics And More
Biotech stocks retreated in the week ending April 14, lock-stepping with the broader market. The news flow was light during the holiday-shortened week and ahead of the imminent first-quarter reporting... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022
Upgrades 
Via Benzinga
Analyzing Sierra Oncology Inc's Short Interest
Sierra Oncology Inc's (NASDAQ:SRRA) short percent of float has fallen 10.32% since its last report. The company recently reported that it has 1.21 million shares sold short, which... 
Via Benzinga
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically... 
Via FinancialNewsMedia
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers 
Via Benzinga
Why Is Creatd (CRTD) Stock Up Today?
Creatd (CRTD) stock is heading higher on Wednesday following news of a deal for wellness beverage subsidiary Dune Glow Remedy. 
Via InvestorPlace
Dear KLDO Stock Fans, Mark Your Calendars for April 28
Kaleido Biosciences (KLDO) stock is soaring on Wednesday but anyone considering a stake in the company will want to keep an eye on April 28. 
Via InvestorPlace
Why Is Sierra Oncology (SRRA) Stock Up Today?
Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring. 
Via InvestorPlace
Sierra Oncology Stock Is Soaring: Here's Why
Sierra Oncology Inc (NASDAQ: SRRA) shares are trading significantly higher Wednesday after the company announced it will be acquired by GlaxoSmithKline PLC (NYSE: GSK) for $55 per share in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022
Upgrades 
Via Benzinga
Biotech Stock Sierra Soars On GSK Buyout As Halozyme Nabs Antares
GlaxoSmithKline said Wednesday it will buy Sierra Oncology for $1.9 billion, sending the biotech stock flying. 
Via Investor's Business Daily
The Daily Biotech Pulse: GlaxoSmithKline And Halozyme Go Shopping, Mylan's Insulin Glargine Recall, Turning Point Shares Lung Cancer Data And More
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Halozyme Buys Specialty Product Company Antares In $960M Deal 
Via Benzinga
SRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
GlaxoSmithKline Scoops Up Rare Cancer-Focused Sierra Oncology In $1.9B Cash Deal
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Stocks That Hit 52-Week Highs On Thursday
On Thursday, 75 stocks made new 52-week highs. Interesting Highlights From Today's 52-Week Highs: The largest company by market cap to hit a new 52-week high... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.